The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Gavrilova S.I.

Mental Health Research Centre

Kolykhalov I.V.

Mental Health Research Center

Kulik A.S.

Mental Health Research Centre

Ponomareva E.V.

Mental Health Research Center

Selezneva N.D.

Mental Health Research Centre

Fedorova Ya.B.

Mental Health Research Centre

Clinical experience of the use of memantal in patients with moderate and severe Alzheimer’s disease

Authors:

Gavrilova S.I., Kolykhalov I.V., Kulik A.S., Ponomareva E.V., Selezneva N.D., Fedorova Ya.B.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2): 52‑57

DOI: 10.17116/jnevro20161162152-57

Read: 1274 times

Download PDF (RU)
Contact the author
Table of contents

CLINICAL EXPERIENCE OF THE USE OF MEMANTAL IN PATIENTS WITH MODERATE AND SEVERE ALZHEIMER’S DISEASE
CLINICAL EXPERIENCE OF THE USE OF MEMANTAL IN PATIENTS WITH MODERATE AND SEVERE ALZHEIMER’S DISEASE

To cite this article:

Gavrilova SI, Kolykhalov IV, Kulik AS, Ponomareva EV, Selezneva ND, Fedorova YaB. Clinical experience of the use of memantal in patients with moderate and severe Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2):52‑57. (In Russ.)
https://doi.org/10.17116/jnevro20161162152-57

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Non-invasive biomarkers for early diagnosis of Alzheimer’s disease in bodily fluids. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):8-16
The expe­rience of diagnosing Alzheimer’s disease based on the study of cere­brospinal fluid biomarkers. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):91-97
The asso­ciation of NOS1AP gene poly­morphisms with the dura­tion of the QT inte­rval in patients with schi­zophrenia receiving anti­psychotic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):98-104
Neurobiological pote­ntial of astragaloside IV and prospects for its use in the treatment of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):7-12
Combined treatment of patients with acute muscular tonic syndrome with dorsopathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):70-77
Stress and sleep: Neurobiological aspe­cts and modern options of inso­mnia therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):14-21
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
Resu­lts of the All-Russian consensus conference on complications in bariatric surgery. Endo­scopic Surgery. 2025;(1):15-24
Pharmacological treatment and prevention of ischemia-reperfusion syndrome in percutaneous coro­nary inte­rvention. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):191-200
Influence of griseofulvin on inte­stinal microbiota in the treatment of microsporia in rural children. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(2):185-190
Abstract:

OBJECTIVE

To assess the efficacy and safety of memantal, a generic formulation of memantine, in patients with moderate and severe dementia due to Alzheimer’s disease (AD).

MATERIAL AND METHODS

Thirty patients with moderate and severe AD, aged from 55 to 84 years, were examined. Memantal was used in the dose of 20 mg per day after the titration period. Duration of treatment was 3 months.

RESULTS

To the end of the study, there was a moderate positive effect as assessed by the CGI. During the treatment, cognitive functions and different forms of daily activity have improved. Significant positive changes in behavioral symptoms of dementia were noted. No adverse effects were observed during the treatment.

CONCLUSION

The results of the analysis revealed the clinical efficacy and safety of memantal in treatment of AD.

Keywords:

Alzheimer’s disease
treatment
memantine
memantal

Authors:

Gavrilova S.I.

Mental Health Research Centre

Kolykhalov I.V.

Mental Health Research Center

Kulik A.S.

Mental Health Research Centre

Ponomareva E.V.

Mental Health Research Center

Selezneva N.D.

Mental Health Research Centre

Fedorova Ya.B.

Mental Health Research Centre

Close metadata

References:

  1. World Alzheimer Report 2015. The Global Impact of Dementia An analysis of prevalence, incidence, cost and trends. Published by Alzheimer’s Disease International (ADI), London. 2015;82.  https://www.alz.co.uk/research/World Alzheimer Report2015.pdf
  2. Belousov Y.B., Zyryanov S.K., Belousov D.Y., Beketov A.S. Clinical and economic aspects of Alzheimer's disease therapy in Russia. Quality Clinical Practice. 2009;1:3-28 
  3. Dementia: A public health priority. Geneva WHO; 2012;102.  https://www.who.int/mental_health/ publications/dementia_report_2012
  4. Farlow MR, Cummings JL. Effective pharmacologic management of Alzheimer disease. American journal of medicine. 2007;120:388-397.  https://doi.org/10.1016/j.amjmed.2006.08.036
  5. Waldemar G, Dubois B, Emre M, Georges J, McKeith IG, Rossor M, Scheltens P, Tariska P, Winblad B. EFNS. Recommendations for the diagnosis and management of Alzheimer’s disease and other disorders associated with dementia: EFNS guideline. European Journal of Neurology. 2007;14:1-26.  https://doi.org/10.1111/j.1468-1331.2006.01605.x
  6. Guidelines for Geriatric Psychiatry. Edited by S.I. Gavrilova Moscow: Pulse Publishers; 2014.
  7. Buckley JS, Salpeter SR. A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence. Drugs Aging. 2015;32(6):453-467.  https://doi.org/10.1007/s40266-015-0266-9
  8. Alva G, Cummings JL, Resnick M, Tocco M, Graham SM. Comparative Safety and Tolerability of Alzheimer’s Disease Treatments. Journal of the American Medical Directors Association. 2008;9(3):B9.  https://doi.org/10.1016/j.jamda.2007.12.070
  9. Gantman M.V. Mental health of caregivers of patients with Alzheimer's disease. Psychiatry. 2014;1(61):61-67. 
  10. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Jörg Möbius H. Memantine in moderate-to-severe Alzheimer’s disease. New England Journal of Medicine. 2003;348:1333-1341. https://doi.org/10.1056/NEJMoa013128
  11. Bullock R. Efficacy and safety of memantine in moderate to severe Alzheimer’s disease: the evidence to date. Alzheimer Disease & Associated Disorders. 2006;20(1):23-29.  https://doi.org/10.1097/01.wad.0000201847.29836.a5
  12. Robinson DM, Keatinq GM. Memantine: a review of its use in Alzheimer’s disease. Drugs. 2006;66(11):1515-1534. https://doi.org/10.2165/00003495-200666110-00015
  13. Plosker GL, Lyseng-Williamson KA. Memantine: a pharmacoeconomic review of its use in moderate to severe Alzheimer’s disease. Pharmacoeconomics. 2005;23(2):193-206.  https://doi.org/10.2165/00019053-200523020-00010
  14. Lubov E.B. Pharmacoeconomic prognosis of long-term therapy with acathinol (memantine) for Alzheimer's disease. Journal of Social and Clinical Psychiatry. 2011;3:84-88. 
  15. Gavrilova S.I., Kalyn Y.B., Gerasimov N.P., Sokolova O.N. A new form of specialized care for elderly patients with dementia: epidemiological and pharmacoeconomic aspects. Journal of Social and Clinical Psychiatry. 2008;2:36-40. 
  16. Kutashev V.A., Samsonov A.S. Compliance and quality of Alzheimer's disease therapy with memantal. RMJ. Neurology. Psychiatry. 2014;11:1603-1607.
  17. Shiryaev O Yu, Shapovalov D L, Polozova T M, Goncharova O V, Kuznetsova N A, Cherenkova E V, Fedorova E Yu. A comparison of the efficacy and safety of memantal and original memantine in the treatment of mild and moderate dementia in Alzheimer’s disease. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2015;115(10):56-61. (In Russ.). https://doi.org/10.17116/jnevro201511510156-61
  18. Mecocci P, Bladström A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer’s disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. International Journal of Geriatric Psychiatry. 2009;24(5):532-338.  https://doi.org/10.1002/gps.2226
  19. Wilkinson D, Wirth Y, Goebel C. Memantine in patients with moderate to severe Alzheimer’s disease: meta-analyses using realistic definitions of response. Dementia and Geriatric Cognitive Disorders. 2014;37(1-2):71-85.  https://doi.org/10.1159/000353801
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.